Antitumor agent for acute myeloid leukemia

Abstract

The present invention addresses the problem of providing an antitumor agent for acute myeloid leukemia, the antitumor agent exhibiting practical effects on acute myeloid leukemia. According to the present invention, provided is an antitumor agent for acute myeloid leukemia, the antitumor agent containing a compound, such as (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)-4-pentyn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methyl-2-butenamide, represented by general formula [1] specified in the present specification, or a salt thereof, wherein the amount of the antitumor agent administered per dose is within a predetermined range.

Description

technical field

[0001] The invention relates to an antitumor agent for acute myelogenous leukemia. Background technique

[0002] Nitrogen-containing heterocyclic compounds having excellent Fms-like tyrosine kinase 3 (FLT3) inhibitory activity and useful as raw materials for pharmaceuticals have been reported (Patent Document 1 and Patent Document 2). Also, a pharmaceutical composition for treating FLT3 mutation-positive cancer comprising the above nitrogen-containing heterocyclic compound has been reported (Patent Document 3). Furthermore, a production method of a nitrogen-containing heterocyclic compound and an intermediate thereof have been reported (Patent Document 4). Hereinafter, the compound represented by the general formula [1] described in Patent Document 3 or its salt may be abbreviated as compound A in some cases.

[0003] prior art literature

[0004] patent documents

[0005] Patent Document 1: International Publication No. 2013 / 157540 Pamphlet

[0006] Pat...

Images